**TrivarX Limited**
**Appendix 4E**
**Preliminary final report**

## 1. Details of reporting period

| | |
|---|---|
| Name of entity: | TrivarX Limited (the Company) |
| ABN: | 58 008 130 336 |
| **Reporting period:** | **30 June 2026** |
| Previous period: | 30 June 2025 |
| Presentation Currency | Australian Dollar ($) |

## 2. Results for announcement to the market

| Key information | 30 June 2026 $ | 30 June 2025 $ | Increase/ (decrease) % | Amount change $ |
|---|---|---|---|---|
| Revenues from ordinary activities | 14,566 | 1,128,979 | (98.71) | 1,114,413 |
| Total comprehensive loss attributable to members | (8,915,118) | (972,663) | 816.57 | 7,942,455 |
| Net loss for the year attributable to members | (8,762,643) | (943,231) | 829.00 | 7,819,412 |

| | Amount per Security | Franked Amount per Security |
|---|---|---|
| Final Dividend | Nil | Nil |
| Interim Dividend | Nil | Nil |
| Previous Corresponding Period | Nil | Nil |
| Record Date for Determining Entitlements | Not applicable | Not applicable |

**Commentary on results:**

## 3. Statement of Profit or Loss and other Comprehensive Income

Refer to attached financial statements

## 4. Statement of Financial Position

Refer to attached financial statements

## 5. Statement of Cash Flows

Refer to attached financial statements

## 6. Statement of Changes in Equity

Refer to attached financial statements

## 7. Dividends

No dividends declared in the current or prior year

## 8. Details of Dividend Reinvestment Plans

Not applicable

## 9. Net Tangible Assets Per Share

| | 30 Jun 2026 | 30 Jun 2025 |
|---|---|---|
| Net tangible asset backing per ordinary security (cents) | 0.18 | 0.10 |

## 10. Details of entities over which control has been gained or lost during the period

**Control gained over entities**

| | |
|---|---|
| Name of entity (or group of entities) | N/A |
| Date control gained | N/A |
| Contribution of such entities to the reporting entity's profit/(loss) from ordinary activities during the period (where material) | N/A |
| Profit/(loss) of the controlled entity (or group of entities) whilst controlled during the whole of the previous corresponding period (where material) | N/A |

**Loss of control over entities**

| | |
|---|---|
| Name of entity (or group of entities) | N/A |
| Date control lost | N/A |
| Contribution of such entities to the reporting entity's profit/(loss) from ordinary activities during the period (where material) | N/A |
| Profit/(loss) of the controlled entity (or group of entities) whilst controlled during the whole of the previous corresponding period (where material) | N/A |

## 11. Details of Associates and Joint Venture entities

| | |
|---|---|
| Name of associate or joint venture entity | N/A |
| Reporting entity's percentage holding in this entity | N/A |
| Contribution to net profit/(loss) (where material) | N/A |
| Aggregate share of profits/(losses) of the above entity (where material) | N/A |

## 12. Any other significant information needed by an investor to make an informed assessment of the Company's financial performance and financial position

Refer to attached financial statements

## 13. Foreign entities

Refer to attached financial statements

## 14. Commentary on results for period and explanatory information

Refer to commentary on page 6 of the attached preliminary report.

### 15. Audit

This Preliminary final report is based on accounts which are in the process of being audited. It is likely that the Auditor will issue an Independent Auditor's Report that will contain an 'Emphasis of Matter' paragraph drawing attention to a material uncertainty that may cast a significant doubt about the Group's ability to continue as a going concern. The attached Preliminary Final Report has been prepared on a going concern basis. Please refer to note 2 Going Concern.

Authorised for release by the Board

Mr David Trimboli
***Non-Executive Chair***

27 August 2026

**TrivarX Limited**
**Statement of profit or loss and other comprehensive income**
**for the year ended 30 June 2026**

| | Note | Consolidated 2026 $ | Consolidated 2025 $ |
|---|---|---|---|
| **Revenue** | | | |
| Other income | | 14,566 | 1,128,979 |
| | | | |
| **Expenses** | | | |
| Employee costs | | (1,095,675) | (974,333) |
| Research and development expenses | | (10,344) | (26,393) |
| Finance costs | | (12,489) | (33,627) |
| Depreciation | | (37,310) | (52,467) |
| Amortisation expenses | 4 | (6,435,579) | - |
| Impairment expenses | 4 | (342,449) | - |
| Other expenses | 3 | (843,363) | (985,390) |
| | | | |
| **Loss before income tax expense** | | (8,762,643) | (943,231) |
| | | | |
| Income tax expense | | - | - |
| | | | |
| **Loss after income tax expense for the year attributable to the Owners of TrivarX Limited** | | (8,762,643) | (943,231) |
| | | | |
| **Other comprehensive loss** | | | |
| *Items that may be reclassified subsequently to profit or loss* | | | |
| Foreign currency translation | | (152,475) | (29,432) |
| | | | |
| Other comprehensive loss for the year, net of tax | | (152,475) | (29,432) |
| | | | |
| **Total comprehensive loss for the year attributable to the Owners of TrivarX Limited** | | (8,915,118) | (972,663) |
| | | | |
| Basic loss per share (cents) | | (95.59) | (0.19) |
| Diluted loss per share (cents) | | (95.59) | (0.19) |

*The above statement of profit or loss and other comprehensive income should be read in conjunction with the accompanying notes*

**TrivarX Limited**
**Statement of financial position**
**as at 30 June 2026**

| | Note | Consolidated 2026 $ | Consolidated 2025 $ |
|---|---|---|---|
| **Assets** | | | |
| **Current assets** | | | |
| Cash and cash equivalents | | 2,443,389 | 1,246,838 |
| Other current assets | | 47,139 | 49,929 |
| ***Total current assets*** | | 2,490,528 | 1,296,767 |
| **Non-current assets** | | | |
| Other assets | | 4,367 | 7,756 |
| Right-of-use assets | | 119,777 | 164,259 |
| Intangibles | 4 | 13,920,082 | 12,014,813 |
| ***Total non-current assets*** | | 14,044,226 | 12,186,828 |
| **Total assets** | | **16,534,754** | **13,483,595** |
| **Liabilities** | | | |
| **Current liabilities** | | | |
| Trade and other payables | | 316,170 | 440,006 |
| Lease liabilities | | 35,925 | 34,649 |
| Employee benefits | | 16,722 | 80,653 |
| Other liabilities | | 104,608 | 141,534 |
| ***Total current liabilities*** | | **473,425** | **696,842** |
| **Non-current liabilities** | | | |
| Lease liabilities | | 92,211 | 134,376 |
| ***Total non-current liabilities*** | | **92,211** | **134,376** |
| **Total liabilities** | | **565,636** | **831,218** |
| **Net assets** | | **15,969,118** | **12,652,377** |
| **Equity** | | | |
| Issued capital | 6 | 113,727,018 | 109,959,773 |
| Reserves | | 14,916,867 | 6,604,728 |
| Accumulated losses | | (112,674,767) | (103,912,124) |
| **Total equity** | | **15,969,118** | **12,652,377** |

*The above statement of financial position should be read in conjunction with the accompanying notes*

**TrivarX Limited**
**Statement of changes in equity**
**for the year ended 30 June 2026**

| Consolidated | Issued capital $ | Foreign currency translation reserves $ | Share based payments reserves $ | Accumulated losses $ | Total equity $ |
|---|---|---|---|---|---|
| **Balance at 1 July 2024** | **106,580,333** | **(219,617)** | **6,501,651** | **(102,968,893)** | **9,893,474** |
| Loss after income tax for the year | - | - | - | (943,231) | (943,231) |
| Other comprehensive loss for the year, net of tax | - | (29,432) | - | - | (29,432) |
| Total comprehensive loss for the year | - | (29,432) | - | (943,231) | (972,663) |
| *Transactions with Owners in their capacity as Owners:* | | | | | |
| Net contributions of equity (note 6) | 3,680,650 | - | - | - | 3,680,650 |
| Share-based payments | - | - | 285,494 | - | 285,494 |
| Share issue costs (note 6) | (301,210) | - | 66,632 | - | (234,578) |
| **Balance at 30 June 2025** | **109,959,773** | **(249,049)** | **6,853,777** | **(103,912,124)** | **12,652,377** |

| Consolidated | Issued capital $ | Foreign currency translation reserves $ | Share based payments reserves $ | Accumulated losses $ | Total equity $ |
|---|---|---|---|---|---|
| **Balance at 1 July 2025** | **109,959,773** | **(249,049)** | **6,853,777** | **(103,912,124)** | **12,652,377** |
| Loss after income tax for the year | - | - | - | (8,762,643) | (8,762,643) |
| Other comprehensive loss for the year, net of tax | - | (152,475) | - | - | (152,475) |
| Total comprehensive loss for the year | - | (152,475) | - | (8,762,643) | (8,915,118) |
| *Transactions with Owners in their capacity as Owners:* | | | | | |
| Net contributions of equity (note 6) | 4,394,500 | - | - | - | 4,394,500 |
| Share-based payments | - | - | 8,117,730 | - | 8,117,730 |
| Share issue costs (note 6) | (627,255) | - | 346,884 | - | (280,371) |
| **Balance at 30 June 2026** | **113,727,018** | **(401,524)** | **15,318,391** | **(112,674,767)** | **15,969,118** |

*The above statement of changes in equity should be read in conjunction with the accompanying notes*

**TrivarX Limited**
**Statement of cash flows**
**for the year ended 30 June 2026**

| | Consolidated 2026 $ | Consolidated 2025 $ |
|---|---|---|
| **Cash flows from operating activities** | | |
| R&D grant received | - | 1,031,073 |
| Payments to suppliers and employees | (1,584,101) | (1,258,156) |
| Interest received | 14,566 | 8,722 |
| Other (GST refund) | 63,759 | 56,707 |
| Net cash used in operating activities | (1,505,776) | (161,654) |
| **Cash flows from investing activities** | | |
| Payments for intangibles | (1,168,736) | (2,091,333) |
| Net cash used in investing activities | (1,168,736) | (2,091,333) |
| **Cash flows from financing activities** | | |
| Proceeds from issue of shares | 3,922,129 | 2,734,321 |
| Proceeds from borrowings | - | 500,000 |
| Repayment of borrowings | - | (500,000) |
| Transaction costs related to loans and borrowings | - | (28,088) |
| Payment of lease liabilities | (47,964) | (55,108) |
| Net cash provided by financing activities | 3,874,165 | 2,651,125 |
| Net increase in cash and cash equivalents | 1,199,653 | 398,138 |
| Cash and cash equivalents at the beginning of the financial year | 1,246,838 | 848,096 |
| Effects of exchange rate changes on cash and cash equivalents | (3,102) | 604 |
| **Cash and cash equivalents at the end of the financial year** | **2,443,389** | **1,246,838** |

*The above statement of cash flows should be read in conjunction with the accompanying notes*

**Note 1. General information**

TrivarX Limited (‘TrivarX, ‘the Company’, or ‘the Parent’) is a for profit company limited by shares incorporated in Australia whose shares are publicly traded on the Australian Securities Exchange.

**Note 2. Basis of preparation**

The preliminary final report has been prepared in accordance with Australian Accounting Standards and Interpretations issued by the Australian Accounting Standards Board ('AASB') and the *Corporations Act 2001*, as appropriate for for-profit oriented entities. The preliminary final report also complies with International Financial Reporting Standards as issued by the International Accounting Standards Board ('IASB').

This preliminary final report has been prepared in accordance with ASX Listing Rules as they relate to the Appendix 4E and in accordance with the recognition and measurement requirements of the Australian Accounting Standards, other authoritative pronouncements of the Australian Accounting Standards Board, Urgent Issues Group Interpretations and the *Corporations Act 2001*. As such, this preliminary final report does not include all the notes of the type included in an annual financial report and accordingly, should be read in conjunction with the annual report for the year ended 30 June 2025 and any ASX announcements made by the Company during the period.

***Going concern***

The preliminary final report has been prepared on the going concern basis, which contemplates the continuity of normal business activity and the realisation of assets and settlement of liabilities in the normal course of business. The Group incurred a loss for the year ended 30 June 2026 of $8,762,643 (2025: $943,231) and net cash outflows from operations was $1,505,776 (2025: $161,654). As at 30 June 2026, cash and cash equivalents was $2,443,389 (2025: $1,246,838).

Whilst the Group is expected to be cash-flow negative in the foreseeable future because of research and development activities, the ability of the Group to continue as a going concern is dependent on securing additional funding through equity or debt, or a combination of both to continue to fund its operational and technological development activities. These conditions indicate a material uncertainty that may cast significant doubt about the Group’s ability to continue as a going concern and, therefore, that it may be unable to realise its assets and discharge its liabilities in the normal course of business.

The directors believe the Group will continue as a going concern after consideration of the following factors:

- the Group successfully raised $4,392,000 (before transaction costs) during the financial year ended 30 June 2026 and management has confidence in its ability to raise further capital when required.
- the Group anticipates the receipt, subject to approval, of government grants and tax incentives related to its research and development activities.
- the directors of TrivarX Limited have reason to believe that in additional to the cash flow currently available, the level of expenditure can be managed to meet working capital requirements for at least the next twelve (12) months.

The preliminary final report does not include any adjustments relating to the recoverability and classification of recorded asset amounts or liabilities that might be necessary should the Group not continue as a going concern and meet its debts as and when they become due and payable.

The directors plan to continue the Group’s operations on the basis outlined above and believe there will be sufficient funds for the Group to meet its obligations and liabilities for at least twelve (12) months from the date of this report.

| **Note 3. Other expenses** | **Consolidated** | |
|---|---|---|
| | **2026** | **2025** |
| | **$** | **$** |
| Consulting and advisory expenses | 349,313 | 529,790 |
| Insurance | 47,631 | 72,530 |
| Listing fees and share registry charges | 69,125 | 95,549 |
| Legal fees | 56,884 | 56,382 |
| Other administration expenses | 320,410 | 231,139 |
| | **843,363** | **985,390** |

## Note 4. Intangibles

| | Consolidated 2026 $ | Consolidated 2025 $ |
|---|---|---|
| Development – at cost | 4,247,051 | 4,247,051 |
| Capitalised costs | 725,387 | 679,867 |
| Less: accumulated amortisation | (1,363,077) | - |
| Less: impairment | (2,241,972) | (2,241,972) |
| | 1,367,389 | 2,684,946 |
| | | |
| MEB-001 application development – at cost | 8,592,831 | 8,698,333 |
| Less: accumulated amortization | (4,296,415) | - |
| | 4,296,416 | 8,698,333 |
| | | |
| EurAsia development – at cost | 1,158,480 | 446,072 |
| Less: accumulated amortization | (579,240) | - |
| | 579,240 | 446,072 |
| | | |
| MLB Proof of Concept development – at cost | 342,449 | 185,462 |
| Less: impairment | (342,449) | - |
| | - | 185,462 |
| | | |
| Stabl-Im (refer to note 5 for more information) | 7,873,884 | - |
| Less: accumulated amortization | (196,847) | - |
| | 7,677,037 | |
| | | |
| | **13,920,082** | **12,014,813** |

Reconciliation of the written down values at the beginning and end of the current and previous reporting period are set out below:

| Consolidated | Capitalised development cost $ | MEB-001 $ | CIP0092-EurAsia $ | MLB Proof of Concept $ | Stabl-Im $ | Total $ |
|---|---|---|---|---|---|---|
| Balance at 1 July 2024 | 2,695,897 | 7,433,312 | - | - | - | 10,129,209 |
| Additions | - | 1,258,743 | 446,072 | 185,462 | - | 1,890,277 |
| Foreign exchange variance | (10,951) | 6,278 | - | - | - | (4,673) |
| **Balance at 30 June 2025** | **2,684,946** | **8,698,333** | **446,072** | **185,462** | **-** | **12,014,813** |
| | | | | | | |
| Additions | - | 20,012 | 733,124 | 165,600 | 7,873,884 | 8,792,620 |
| Foreign exchange variance | 45,520 | (125,514) | (20,716) | (8,613) | - | (109,323) |
| Amortisation | (1,363,077) | (4,296,415) | (579,240) | - | (196,847) | (6,435,579) |
| Impairment (i) | - | - | - | (342,449) | - | (342,449) |
| **Balance at 30 June 2026** | **1,367,389** | **4,296,416** | **579,240** | **-** | **7,677,037** | **13,920,082** |

(i) Having assessed the relevant impairment indicators of its intangibles as at 30 June 2026, the Company decided to fully impair the costs associated with the MLB Proof of Concept as this application is not expected to derive any future economic benefits.

## Note 5. Acquisition of Stabl-Im

On 12 December 2025, the Company acquired all intellectual property associated with the Stabl-Im brain imaging technology from Nucleics Pty Ltd (“Acquisition”). The technology has potential to enable safe imaging and monitoring of brain cancers through standard Magnetic Resonance Imaging (MRI). It represents a potential breakthrough in the safe and non-invasive imaging of brain and other cancers. Stabl-Im uses stable isotope labelling of replicating cells within the brain for earlier detection of brain tumours. Trivarx believes that this is an innovative technology to pursue significant opportunities in the diagnostic imaging and neuro-oncological markets. The Acquisition was approved by shareholders at a General Meeting held on 12 December 2025. Amortisation is calculated using the straight-line method over the expected life of the asset, which is no more than 20 years.

The Acquisition was assessed under AASB 3 using the concentration test and analysis of the elements of a business. The Acquisition was determined to be an asset acquisition.

***Consideration***

| | Fair value<br>$ |
|---|---:|
| Non-refundable option fee | 250,000 |
| Performance Shares | 5,500,000 |
| Facilitator Options | 2,123,884 |
| | **7,873,884** |

## Note 6. Issued capital

| | Consolidated | | | |
|---|---:|---:|---:|---:|
| | 2026<br>Shares | 2025<br>Shares | 2026<br>$ | 2025<br>$ |
| Fully paid ordinary shares | 1,153,693,464 | 619,826,341 | 113,727,018 | 109,959,773 |

## Note 6. Issued capital (continued)

*Movements in ordinary share capital*

| Details | Date | Shares | Issue price | $ |
|---|---|---|---|---|
| **Balance** | **30 June 2024** | **409,649,428** | | **106,580,333** |
| Issue of shares | 10 July 2024 | 3,960,000 | $0.0250 | 99,000 |
| Issue of shares | 10 July 2024 | 14,000,000 | $0.0250 | 350,000 |
| Placement | 10 July 2024 | 29,029,255 | $0.0250 | 725,731 |
| Issue of shares | 10 July 2024 | 400,000 | $0.0300 | 12,000 |
| Issue of shares | 4 December 2024 | 7,831,756 | $0.0220 | 172,299 |
| Issue of shares | 14 January 2025 | 1,627,653 | $0.0160 | 26,042 |
| Placement | 24 March 2025 | 56,401,855 | $0.0150 | 846,028 |
| Placement | 24 March 2025 | 46,417,043 | $0.0150 | 696,256 |
| Issue of shares | 25 March 2025 | 422,743 | $0.0190 | 8,032 |
| Issue of shares | 25 March 2025 | 473,314 | $0.0170 | 8,046 |
| Placement | 20 May 2025 | 47,181,102 | $0.0150 | 707,717 |
| Issue of shares | 10 June 2025 | 843,213 | $0.0130 | 10,962 |
| Issue of shares | 10 June 2025 | 1,412,509 | $0.0110 | 15,537 |
| Issue of shares | 10 June 2025 | 176,470 | $0.0170 | 3,000 |
| Share issue costs | | - | | (301,210) |
| **Balance** | **30 June 2025** | **619,826,341** | | **109,959,773** |
| Placement (Tranche 1) | 27 October 2025 | 87,274,663 | $0.0080 | 698,197 |
| Issue of shares | 27 October 2025 | 100,000 | $0.0250 | 2,500 |
| Issue of shares | 2 December 2025 | 8,767,123 | $0.0219 | 192,000 |
| Placement (Tranche 2) | 19 December 2025 | 437,725,337 | $0.0080 | 3,501,803 |
| Share issue costs | | | | (627,255) |
| **Balance** | **30 June 2026** | **1,153,693,464** | | **113,727,018** |

*Ordinary shares*
Ordinary shares entitle the holder to participate in dividends and the proceeds on the winding up of the Company in proportion to the number of and amounts paid on the shares held. The fully paid ordinary shares have no par value and the Company does not have a limited amount of authorised capital.

On a show of hands every member present at a meeting in person or by proxy shall have one vote and upon a poll each share shall have one vote.

*Share buy-back*
There is no current on-market share buy-back.

*Capital Management*
Due to the nature of the Group's activities, the Group does not have ready access to credit facilities, with the primary source of funding being equity and/or debt raisings. Therefore, the focus of the Group's capital risk management is the current working capital position against the requirements of the Group to meet research and development programs and corporate overheads. The Group's strategy is to ensure appropriate liquidity is maintained to meet anticipated operating requirements, with a view to initiating appropriate capital raisings as required. Any surplus funds are invested with major financial institutions.

*Accounting policy for issued capital*
Ordinary shares are classified as equity.

Incremental costs directly attributable to the issue of new shares or options are shown in equity as a deduction, net of tax, from the proceeds.